

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 300,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	Q1/22	Q1/21	Change	FY/21
Sales and Earnings				
Sales	9,720	8,984	8%	37,520
EBIT ¹	996	1,009	-1%	4,252
Net income ^{1,2}	462	436	6%	1,867
Earnings per share in € ^{1,2}	0.83	0.78	6%	3.35
Balance sheet and cash flow				
Total assets	73,114		2%	71,962
Non-current assets	55,112		1%	54,501
Equity ³	30,584		4%	29,288
Equity ratio ³	41.8%			40.7%
Net debt/EBITDA ^{1,4}	3.60			3.51
Investments ⁵	500	533	-6%	3,117
Operating cash flow	101	652	-85%	5,078
Operating cash flow in % of sales	1.0%	7.3%		13.5%
Profitability				
EBIT margin ¹	10.2%	11.2%		11.3%
Return on equity after taxes (ROE) ^{1,2}	9.5%	9.9%		9.8%
Return on operating assets (ROOA) ¹	6.3%	6.9%		6.5%
Return on invested capital (ROIC) ¹	5.6%	6.2%		5.9%
Employees	317,242			316,078

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA


³ Including noncontrolling interests

⁴ At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures

⁵ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of March 31, 2022


BUSINESS SEGMENTS

€ in millions		Q1/22	Q1/21	Change	FY/21
FRESENIUS MEDICAL CARE	Sales	4,548	4,210	8%	17,619
	EBIT ¹	348	474	-27%	1,852
FRESENIUS KABI	Sales	1,847	1,761	5%	7,193
	EBIT ²	293	276	6%	1,153
FRESENIUS HELIOS	Sales	2,931	2,649	11%	10,891
	EBIT ²	306	268	14%	1,127
FRESENIUS VAMED	Sales	513	477	8%	2,297
	EBIT ²	8	-4	--	101

¹ Reported

² Before special items


SALES BY REGION



Q1/22: €9.7 billion

- **Fresenius Medical Care** is the world's largest provider of products and services for individuals with renal diseases. As of March 31, 2022, Fresenius Medical Care was treating 343,493 patients in 4,153 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.
- **Fresenius Kabi** offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
- **Fresenius Helios** is Europe's leading private hospital operator. The company comprises Helios Germany, Helios Spain and Helios Fertility. Helios Germany operates 88 hospitals, ~130 outpatient centers and 6 prevention centers. Helios Spain operates 50 hospitals, 97 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 8 hospitals and as a provider of medical diagnostics. Helios Fertility offers a wide spectrum of state-of-the-art services in the field of fertility treatments.
- **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management to total operational management.

SALES BY BUSINESS SEGMENT




Q1/22: €9.7 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT OF DIVIDENDS IN €



¹ Proposal

GROUP OUTLOOK 2022

	FY/21 Base ¹	Targets 2022 ²
Sales, growth (cc)	€37,520 million	Mid single-digit percentage growth
Net income ³ , growth (cc)	€1,867 million	Low single-digit percentage growth

¹ Before special items, including COVID-19 effects

² Before special items, including estimated COVID-19 effects

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

For the outlook of the business segments please see the Investor News of May 4, 2022.

FRESENIUS SHARE / ADR


	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (March 31, 2022)	558,502,143
Market capitalization (March 31, 2022)	€18.6 billion

ANALYST RECOMMENDATIONS



As of March 31, 2022

FINANCING MIX OF THE FRESENIUS GROUP



FINANCIAL CALENDAR

	Dates
Annual General Meeting	May 13, 2022
Report on 1st half 2022	August 2, 2022
Report on 1st-3rd quarter 2022	November 1, 2022

Please note that these dates could be subject to modifications.
www.fresenius.com/events-and-roadshows

¹ Subject to prior approval by the Annual General Meeting

CONTACT



Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.de

Markus Georgi
Senior Vice President
Investor Relations & Sustainability
Telephone: +49 (0) 61 72/6 08-24 85
Telefax: +49 (0) 61 72/6 08-24 88

Follow us on Social Media:

[linkedin.com/company/fresenius-investor-relations](https://www.linkedin.com/company/fresenius-investor-relations)
 twitter.com/Fresenius_IR

For more information please see the imprint on our corporate website.